NFE2L3 antibody - middle region (ARP33727_P050)
- Known as:
- NFE2L3 (anti-) - middle region (ARP33727_P050)
- Catalog number:
- arp33727_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- NFE2L3 antibody - middle region (ARP33727_P050)
Related genes to: NFE2L3 antibody - middle region (ARP33727_P050)
- Gene:
- NFE2L3 NIH gene
- Name:
- nuclear factor, erythroid 2 like 3
- Previous symbol:
- -
- Synonyms:
- Nrf3
- Chromosome:
- 7p15.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-06-03
- Date modifiied:
- 2015-11-18
Related products to: NFE2L3 antibody - middle region (ARP33727_P050)
Related articles to: NFE2L3 antibody - middle region (ARP33727_P050)
- Ovarian cancer (OC) presents a formidable public health challenge, characterized by rising incidence rates and high mortality. NRF3 (NFE2L3), a cap 'n' collar transcription factor, plays a complex role in the pathogenesis of various diseases, including cancer tumorigenesis and progression. Its regulatory mechanisms, including post-translational modifications and interactions with other transcription factors, are crucial for understanding its impact on cancer biology. A thorough examination of existing literature categorizes upstream and downstream genes, molecules, pathways, and mechanisms associated with NRF3, emphasizing its intricate roles and molecular actions in OC. NRF3 exhibits a dual role as a potential tumor suppressor or oncogene, depending on the cellular context and tumor microenvironment. Evidence from a comprehensive literature search and bioinformatics investigation reveals a pan-cancer link between NRF3 and key processes such as chemoresistance, immune evasion, and metastasis, with elevated expression correlating with poor survival outcomes in OC. Its oncogenic mechanisms within the tumor microenvironment highlight immunosuppressive roles that may compromise therapy responses, underscoring its potential as a theranostic biomarker in OC. Emerging evidence suggests that targeting NRF3 may offer novel therapeutic strategies, potentially enhancing treatment outcomes through combination therapies and immunotherapeutic approaches. Our review emphasizes the necessity for further translational research to validate NRF3 as a therapeutic target and biomarker, aiming to improve patient stratification and treatment efficacy in OC. Ultimately, understanding NRF3's multifaceted roles may pave the way for innovative, personalized treatment strategies that address the unique challenges posed by OC. - Source: PubMed
Publication date: 2026/02/06
Hosseinzadeh MahdiKarimi AbbasRashid MohsenSadegi Mohammad Reza - The current treatment options and therapeutic targets for triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer (BrCA), are limited. This study aimed to identify novel biomarkers and transcriptional regulatory networks (TRN) inherent in TNBC samples. - Source: PubMed
Publication date: 2026/01/19
Modi Shail RakeshAndey TerrickAcquaah-Mensah George - Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Although diagnostic and therapeutic strategies have advanced, the molecular mechanisms driving CRC pathogenesis are not fully understood, highlighting the need for novel biomarkers and therapeutic agents. - Source: PubMed
Publication date: 2026/01/08
Liao QimingXue YulongYu YajiangLiu MengzheYu ZeyuanCheng XiaoxiaZhang LeiJi Xinying - Ovarian cancer (OC) remains the most lethal gynecologic malignancy, primarily due to late-stage diagnosis resulting from nonspecific early symptoms. This study aims to identify novel genetic targets and elucidate the underlying mechanisms driving OC progression by integrating multi-omics datasets. - Source: PubMed
Publication date: 2026/01/21
Feng YueLiu Guoyan - Emodin, a natural anthraquinone, exerts antitumor effects by increasing reactive oxygen species (ROS) and inducing apoptosis, autophagy, and cell-cycle arrest. However, its potential to induce ferroptosis, a distinct iron-dependent cell death, in hepatocellular carcinoma (HCC) remains unexplored. - Source: PubMed
Publication date: 2026/01/12
Ding ZhiranZheng MenghuaMou BingbingLi YuQin BoxinQiu LuYang XuesongRen Yonggang